Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Opko Health Inc (NQ: OPK )

1.510 -0.010 (-0.66%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Opko Health Inc

< Previous 1 2 3 4 5 6 Next >
The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 28) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures Product Safety
Earnings Scheduled For July 29, 2021
Companies Reporting Before The Bell • Smith & Nephew (NYSE:SNN) is projected to report earnings for its second quarter. • Cohen & Co (AMEX:COHN) is... 
Via Benzinga
The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More
Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start... 
Via Benzinga
Exposures Product Safety
Why Bionano Genomics, Invitae, and Opko Health Stocks Sank This Week
The market's pessimism about these diagnostics stocks appeared unrelated to company-specific news. 
Via The Motley Fool
Analyzing OPKO Health's Unusual Options Activity
OPKO Health (NASDAQ:OPK) shares experienced unusual options activity on Thursday. The stock price moved up to $3.56 following the option alert. Sentiment: BULLISH Option Type:... 
Via Benzinga
OPKO Health, CAMP4 Therapeutics Ink Oligonucleotide Platform With Focus On Drug-Resistant Epilepsy
OPKO Health Inc (NASDAQ: OPK) has entered into an exclusive worldwide agreement with privately-held CAMP4 Therapeutics Corporation (CAMP4) to develop,... 
Via Benzinga
OPKO Health, Nicoya Therapeutics Ink Rayaldee Pact For Hyperparathyroidism In Greater China
OPKO Health Inc's (NASDAQ: OPK) subsidiary EirGen Pharma has agreed to develop and commercialize Rayaldee to treat secondary hyperparathyroidism in... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 21, 2021
Upgrades B of A Securities upgraded the previous rating for Cimarex Energy Co (NYSE: 
Via Benzinga
OPKO Health Offloads Fill and Finish Manufacturing Facility in Ireland To Horizon Therapeutics
OPKO Health Inc's (NASDAQ: OPK) subsidiary, EirGen Pharma Ltd, has agreed to sell one of its facilities in Waterford, Ireland, to Horizon Therapeutics plc... 
Via Benzinga
Cramer Shares His Thoughts On MP Materials, Nokia And More In 'Lightning Round'
On CNBC's "Mad Money Lightning Round," Jim Cramer said he would pass on Opko Health Inc. (NASDAQ: OPK). BOSTON OMAHA Corp (NASDAQ: BOMN) is a hard pass, said Cramer... 
Via Benzinga
10 Health Care Stocks Showing Unusual Options Activity In Today's Session
This unusual options alert can help traders discover the next big trading opportunities. Traders will search for circumstances when the market estimation of an option diverges... 
Via Benzinga
Opko Health (OPK) Q1 2021 Earnings Call Transcript
OPK earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
OPKO Health: Q1 Earnings Insights
Shares of OPKO Health (NASDAQ:OPK) rose in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 155.56% over the past year to $0.... 
Via Benzinga
The Daily Biotech Pulse: FDA Rejection For Protalix, Amgen Q1 Trail Estimates, Pfizer Goes Shopping
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 27) Aldeyra Therapeutics, Inc... 
Via Benzinga
Exposures Product Safety
Earnings Scheduled For April 28, 2021
Companies Reporting Before The Bell • M/I Homes (NYSE:MHO) is likely to report quarterly earnings at $1.51 per share on revenue of $758.77 million. • Melco... 
Via Benzinga
The Week Ahead In Biotech (April 25-May 1): FDA Decisions For Sol-Gel, Protalix Bio, Ardelyx
Biopharma stocks came back from the weakness seen in the first two sessions to close the week ended April 23 higher. Johnson & Johnson (NYSE: JNJ) and Roche Holding AG (OTC:... 
Via Benzinga
Exposures Product Safety
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.